CARD and Lineagen, Inc. today announced the launch of a new clinical partnership to offer Lineagen’s FirstStepDx® genetic test to patients and their families. FirstStepDx is a whole-genome genetic test customized with validated, novel proprietary genetic variants associated with autism spectrum disorders (ASD). Under the terms of the partnership agreement, FirstStepDx, integrated with a pre-and posttest genetic counseling service and personalized reporting, will be offered to clients receiving treatment using CARD’s innovative Skills® program. FirstStepDx is the first program of its kind, designed to meet current clinical guidelines that recommend chromosomal microarray analysis as a first-line genetic test as part of a comprehensive diagnostic evaluation of individuals with ASD.
Doreen Granpeesheh, Ph.D., BCBA-D, CARD Founder and Executive Director, commented, “We are constantly seeking new opportunities to enhance our services with proven research. Recent scientific literature and clinical guidelines have recommended genetic testing and counseling for children with autism spectrum disorders. In selecting a partner in this area, CARD chose Lineagen’s FirstStepDx because it includes the most advanced technology, complemented by the personal service similar to that provided by CARD to each client and family.”
Michael S. Paul, Ph.D., Lineagen’s Chief Executive Officer, stated, “We are very pleased to initiate our clinical partnership program with CARD. Identification of genetic variants associated with ASD, as well as other disorders of childhood development, with our FirstStepDx test furthers the understanding of the etiology for these disorders and may aid physicians and treatment specialists to more accurately guide clinical management. We look forward to providing children who are receiving the best treatment at CARD with the best genetic testing and genetic counseling service currently available.”